SCHEMBL21097482

SCHEMBL21097482

O=C1COc2ccc(C(=O)N3CCC(C(=O)c4ccccc4)CC3)cc2N1

nearest known ligand 0.56

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 4/20 0.56
MGLL Q99685 9/20 0.55
GAA P10253 2/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
HSD11B1 P28845 1/20 0.53
TRPV1 Q8NER1 1/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30541688 1.00 NR3C2 (0.56) NR3C2MGLLGAAMEN1KMT2A
SCHEMBL531974 0.86 PARP1 (0.62) NR3C2MGLLGAATRPV1ALDH1A1
SCHEMBL21061725 0.85 NR3C2 (0.53) NR3C2MGLLGAATRPV1ALDH1A1
SCHEMBL30541711 0.85 NR3C2 (0.53) NR3C2MGLLGAATRPV1ALDH1A1
SCHEMBL21061846 0.83 MGLL (0.54) NR3C2MGLLGAAALDH1A1LMNA
SCHEMBL22491399 0.83 ALDH1A1 (0.56) NR3C2MGLLGAAMEN1KMT2A
SCHEMBL30541708 0.83 MGLL (0.59) NR3C2MGLLGAAMEN1KMT2A
SCHEMBL29734602 0.83 ALDH1A1 (0.56) NR3C2MGLLGAAMEN1KMT2A
SCHEMBL22491438 0.83 GAA (0.54) NR3C2MGLLGAATRPV1ALDH1A1
SCHEMBL21061872 0.83 MGLL (0.59) NR3C2MGLLGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183224-A1 BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-06-15 US claimed
US-20200308158-A1 BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2020-10-01 US claimed
US-20230183224-A1 BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-06-15 US disclosed
US-20230183224-A1 BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-06-15 US disclosed
US-20200308158-A1 BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2020-10-01 US disclosed
US-20200308158-A1 BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2020-10-01 US disclosed
WO-2019115660-A1 BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2019-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183224-A1 BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS LPL, LIPC, PNLIP NR3C2 2686/4885MGLL 4/4885GAA 28/4885
US-20200308158-A1 BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS LPL, LIPC, PNLIP NR3C2 2686/4885MGLL 4/4885GAA 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.